Cancer News and Research

Latest Cancer News and Research

EpiCept enters definitive agreements to purchase 8.9 million shares of common stock

EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 8.9 million shares of its common stock at $0.80 per share, and five-year warrants to purchase up to approximately 3.6 million shares of common stock at an exercise price of $0.75 per share.

8 Feb 2011

Study on non-surgical approach for treatment of liver hydatidosis

Concerning treatment, until recently the only definitive treatment for hydatid disease had been surgery. Different surgical techniques and procedures have been carried out and even in some cases, a liver transplant has been required. Advances in drug therapy has been influenced by the introduction of albendazole and accelerated by addition of praziquantel, but this requires a long period of treatment i.e. up to a year or more, and is not effective for everyone.

8 Feb 2011

Munich research team provides promising alternative to DNA-based procedures

Defects in the genome are the cause of many diseases. Gene therapy - direct replacement of mutant genes by intact DNA copies - offers a means of correcting such defects. Now a research team based at the Medical Center of the University of Munich, and led by Privatdozent Dr. Carsten Rudolph, has taken a new approach that avoids DNA delivery.

8 Feb 2011

Researchers identify enzyme that protects against inflammation, joint destruction

A team of researchers at the University of Gothenburg, Sweden, has identified an enzyme that protects against inflammation and joint destruction. Made when the researchers blocked production of the enzyme GGTase-I in transgenic mice, this unexpected discovery could lead to the identification of new mechanisms that control the development of inflammatory disorders, as well as new medicines.

8 Feb 2011

Executive wellness a legit corporate expense

At least once a year, executives from Ciena Corp. spend a day at Johns Hopkins University getting poked and prodded as they undergo tests for a barrage of potential ailments, from anemia to prostate cancer. They

8 Feb 2011

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.

8 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

Nutritional deficiencies among indigenous populations: two studies

They find iodine deficiency for the first time among an Aboriginal population in the NT. This deficiency was previously thought to occur only in the nation’s south-eastern states. The study involved nearly 400 teenagers of aboriginal origin living in remote as well as urban areas of the Darwin Health Region, which covers 120,000 km-square of the top end of the NT.

7 Feb 2011

Viewpoints: (Still) Debating health law's constitutionality; Food labels; Lawmakers' abortion divide

For state governments, the bill presents huge new costs, as we are required to enroll 15 million to 20 million more people in our Medicaid systems. ... Perhaps worse, the law expects to conscript the states as its agents in its takeover of health care. It assumes that we will set up and operate its new insurance "exchanges" for it (Indiana Gov. Mitch Daniels, 2/7).

7 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

7 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

Patients with kidney tumours can benefit from nephron-sparing surgery

Patients with kidney tumours larger than four centimetres are much more likely to enjoy good long-term renal function if they undergo nephron-sparing surgery rather than radical nephrectomy, according to a study in the February issue of the urology journal BJUI.

7 Feb 2011

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

DermTech International, a biotechnology company dedicated to bringing genomic medicine to dermatologists, today announced that the discovery data on its new genomic assay for melanoma have been published in the British Journal of Dermatology.

7 Feb 2011

Court filings: Tobacco companies seek to block public disclosure of proposed statements

According to court filings, the tobacco companies are seeking to block public disclosure of proposed statements a federal judge has ordered them to make to correct their deceptions about their deadly products.

7 Feb 2011

Allergies appear to reduce glioma risk

The more allergies one has, the lower the risk of developing low- and high-grade glioma, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

7 Feb 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011

Genomic study identifies link between Native American ancestry, relapse in young leukemia patients

The first genome-wide study to demonstrate an inherited genetic basis for racial and ethnic disparities in cancer survival linked Native American ancestry with an increased risk of relapse in young leukemia patients. The work was done by investigators at St. Jude Children's Research Hospital and the Children's Oncology Group.

6 Feb 2011

New research: Binge drinking in rural areas is more of a problem than previously thought

Binge drinking is often considered to be a problem of towns and cities but new research published in BioMed Central's open access journal BMC Public Health shows that binge drinking in rural areas is more of a problem than previously thought.

6 Feb 2011

Cancer News and Research

Latest Cancer News and Research

EpiCept enters definitive agreements to purchase 8.9 million shares of common stock

Study on non-surgical approach for treatment of liver hydatidosis

Munich research team provides promising alternative to DNA-based procedures

Researchers identify enzyme that protects against inflammation, joint destruction

Executive wellness a legit corporate expense

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Nutritional deficiencies among indigenous populations: two studies

Viewpoints: (Still) Debating health law's constitutionality; Food labels; Lawmakers' abortion divide

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Patients with kidney tumours can benefit from nephron-sparing surgery

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

Court filings: Tobacco companies seek to block public disclosure of proposed statements

Allergies appear to reduce glioma risk

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Genomic study identifies link between Native American ancestry, relapse in young leukemia patients

New research: Binge drinking in rural areas is more of a problem than previously thought

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in